Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2018

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

pharmaceutical companies pharma intelligence

The partner of choice for pharmaceutical companies

Bring game-changing drugs to market more efficiently. We’ll help you understand the competition to hone in on your strategies to improve healthcare and patient outcomes.

Get drugs to market faster

adevelopment partner pharma intelligence

The right drugs developed at the right time transform pharmaceutical and biotechnology companies and improve patients’ lives. But the process is long and complex, taking place in an ever-changing, intensely competitive arena.

How we help
As the trusted pharma research partner of the top 50 global pharmaceutical companies, we provide reliable, timely intelligence and insights to help you every step of the way during drug development.

We can help you:

Optimize your clinical trials
Stay ahead of the competition by fully understanding future patient needs
Tailor your portfolio and commercial strategies to market needs
Identify opportunities and overcome potential threats across your pipeline
Stay current and be prepared for market shifts
Access historical success rates, and development and regulatory durations from a large number of perspectives

Our unique strengths

Identify market opportunities

Understand where future drug and development opportunities lie with access to the industry’s leading forecasts and behind-the-headlines analysis.

Capitalize on treatment trends

Keep on top of global trends and access source information on the impact of developing technologies.

Approach reimbursement proactively

Our reimbursement analysis can assist your business planning – both at the early stages of product development and long after product launch.

View competitor activity

Get unique competitor insight with our detailed reviews of your competitors’ clinical trials and our ability to track all drugs in development.

View more
View Less

Relevant products

Thought leadership

Key benefits:

Build brand credibility
Generate Leads
Effective reporting

Lead generation

Key benefits:

Direct access to your target Pharma audience
Multi or single channel campaigns
Measurable results

Our products and audiences

Key benefits:

Tailored and targeted campaigns
Multiple channels and content formats
Right message for the right audience

View all content

Scrip

Eisai's Obesity Drug Belviq Passes Cardiovascular Outcomes Test

By Emily Hayes 18 Jul 2018

The Japanese pharma says it will discuss the data with US FDA, with hopes of potential to incorporate secondary endpoint data in labeling.

Topic Obesity Clinical trials

View article
Scrip

As J&J Sees Continued Drug Price Declines, CEO Urges Slow Policy Change Via Trump's Blueprint

By Jessica Merrill 18 Jul 2018

J&J told investors to anticipate negative net drug pricing of 4%-6% across its portfolio in 2018, following a 4.6% negative impact in 2017. CEO Alex Gorsky also cautioned against changing drug pricing policy too quickly.

Topic Policy and regulation

View article
Scrip

Authorities Find Accounting Violation By Samsung BioLogics, Prosecutors To Probe

By Jung Won Shin 13 Jul 2018

South Korean financial authorities conclude Samsung BioLogics violated accounting standards by omitting certain information on its joint venture agreement with Biogen from public disclosures, and have ordered further investigation of a corporate governance decision on the handling in accounts of the JV, Samsung Bioepis. The latest ruling in the prolonged affair could hurt the credibility and business of Samsung BioLogics going forward, although the firm maintains it has done nothing improper.

Topic Policy and regulation

View article
Scrip

Mylan's Fulphila Sets Up The US Market For The Next Biosimilar Showdown

By Jessica Merrill 13 Jul 2018

Mylan has priced its biosimilar version of pegfilgrastim at a 33% discount to Amgen's WAC for Neulasta, steeper than the 15% discount Pfizer initially offered for Inflectra. The commercial outcome for Fulphila could set the tone for future US biosimilars, which have yet to take off.

Topic Biosimilars Business strategies

View article
Rose Sheet

Hawaii's Sunscreen Ingredient Ban Is On The Books; To Industry, An Affront To Science

By Lauren Nardella 12 Jul 2018

As in the case of plastic microbeads some four years ago, the personal-care industry finds itself in the position of having to reformulate potentially on a mass scale due to environmental rather than human safety concerns. And once again the legislation was driven in large part by shoddy science, industry says.

Topic Policy and regulation

View article
Rose Sheet

EU Watch: Next Steps Re Controversial CMR Ban Approach, Fragrance Allergens Labeling

By Ryan Nelson 12 Jul 2018

EU sources update Rose Sheet on contentious initiatives to cement the Commission’s pathway for banning carcinogenic, mutagenic or reprotoxic substances in cosmetics and to promote fragrance allergen awareness and risk management.

Topic Policy and regulation

View article
Scrip

Downward, Eastward or Inward? Blockbuster Film Puts Cancer Drug Prices In China Spotlight

By Brian Yang 11 Jul 2018

Bagging a $200m box office in its opening week in China, "Dying to Survive" is a sentimental movie about a Chinese businessman selling cancer drugs smuggled from India but unapproved in China that sees his life taking a drastic turn, from convicted felon to a Robin Hood-like hero as he helps those in need. The Chinese film authority’s clearance for the screening of the movie and the smash success signal three key messages about the future potential direction of oncology drugs in the country.

Topic Cancer

View article
Scrip

Pfizer Agrees To Roll Back Prices On 40 Drugs, Yielding To Pressure From Trump

By Jessica Merrill 11 Jul 2018

After a conversation with President Trump, CEO Ian Read agreed to cancel price increases on 40 drugs that took effect July 1, to give the administration time to work on its blueprint for improving the health care system.

Topic Policy and regulation

View article
Scrip

How Ovarian Cancer Maintenance Therapies Stack Up On Costs And Value

By Emily Hayes 06 Jul 2018

With new branded immunotherapy-based double- or triple-drug combinations on the way, there is greater scrutiny of costs and efficiency.

Topic Cancer

View article
Scrip

Drayson Outlines Ambition To Build Clinician-Driven AI Business Using NHS Data

By Mike Ward 06 Jul 2018

Former UK science minister Lord Drayson explains to Scrip his plans for Sensyne Health, an Oxford, UK-based AI-focused healthcare technology company, to go public after securing a second deal with an NHS Foundation Trust while seeking big pharma research collaborations.

Topic Business strategies

View article
Scrip

Competitive Strategies Critical As EMA Decides On Kymriah And Yescarta

By Neena Brizmohun 28 Jun 2018

With Novartis’s and Kite’s CAR T-cell therapies both expected to gain recommendations for pan-EU approval this week, discounts will need to be negotiated for these new treatments to reach the markets in Europe.

Topic Cell and gene therapy

View article
Scrip

AbbVie Calico Extend Their Collaboration On Aging

By Joseph Haas 28 Jun 2018

The pharma and the Google spinout focused on aging are adding $1bn in funding to their 2014 collaboration, which has yielded more than two dozen preclinical candidates so far.

Topic Alzheimers

View article
Scrip

ADA Meeting's Around The Corner: Five Things To Watch For

By Emily Hayes 21 Jun 2018

Among other debates at the American Diabetes Association annual meeting, clinicians will discuss the future of cardiovascular outcomes studies for diabetes drugs – whether they should maintain course or are due for an overhaul.

Topic Diabetes

View article
Scrip

Learning From Human Cell Hijacking Masters: ENYO Pharma Takes Virus Tricks Into Drug Discovery

By Eleanor Malone 21 Jun 2018

Emerging Company Profile: ENYO Pharma has been around for barely four years, but it is already advancing its lead programs into Phase II trials in hepatitis B and NASH, and anticipates many more uses for its virology-based platform that will go way beyond treating virus infections.

Topic Company analysis Hepatitis B

View article
Awareness

Global Generics Podcast 2018

20 Jun 2018

Listen to this podcast with Generics bulletin editor Aidan Fry and deputy editor David Wallace. The Global Generics & Biosimilars Awards reward ‘best practice’ in the two industries, while at the same time encouraging improvements in every aspect of the way business is conducted.

Full podcast

Latest headlines

Scrip

18 Jul 2018

Korea Eyes New Consortium To Support Innovation, Nurture Biotech Hubs

Link
Scrip

17 Jul 2018

Roche Steps Closer To Flu Market Domination With Phase III Baloxavir Results

Link
Scrip

17 Jul 2018

Eisai's Obesity Drug Belviq Passes Cardiovascular Outcomes Test

Link
Scrip

17 Jul 2018

Eight Pivotal Trial Read-Outs Expected In Q3

Link
Scrip

17 Jul 2018

With First IND, Recursion Readies Its AI, Experimental Biology Approach For The Clinic

Link
Scrip

17 Jul 2018

J&J's Invokana Slows CKD Progression In Diabetes

Link
Scrip

16 Jul 2018

Aurobindo Aims For Europe Growth With Apotex Acquisitions

Link
Scrip

16 Jul 2018

Cystic Fibrosis: NovaBiotics Advances Old Dog With New Tricks

Link
Scrip

16 Jul 2018

SK Acquires AMPAC, On Track To Meet Global Contract Manufacturing Ambitions

Link
Scrip

16 Jul 2018

Siga Ready For Next Phase, New Cash With Smallpox Drug Approval

Link
Scrip

13 Jul 2018

Pharma Q2 Results Preview: Johnson & Johnson And Novartis

Link
Scrip

13 Jul 2018

Pipeline Watch: Phase III Starts With QPI-1002, Enfortumab Vedotin And ZYN-002

Link
Scrip

13 Jul 2018

Amgen Puts Evenity Filing Back On Track With TIMI Cardiovascular Risk Review

Link
Scrip

13 Jul 2018

Job Cuts Seen At Dr Reddy’s Amid Cost Recalibration

Link
Scrip

13 Jul 2018

Deal Watch: BioCryst Shareholder Dissent Scuttles Planned Merger With Idera

Link

Next steps

Request a live demo

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

How can we help you?

Our team is always happy to hear from you. Please call us at:

US Toll-Free : +1 888 670 8900
US Toll : +1 908 547 2200
UK & Europe : +44 (20) 337 73737
Australia : +61 2 8705 6907
Japan : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

The partner of choice for pharmaceutical companies

Get drugs to market faster

Our unique strengths

Identify market opportunities

Capitalize on treatment trends

Approach reimbursement proactively

View competitor activity

Relevant products

Below are the Product List

Thought leadership

Lead generation

Our products and audiences

Pharma Intelligence latest insights

Latest headlines

Next steps

This is Contactus Section

Request a live demo

How can we help you?

Pharma Report Store